Brief: Algernon Pharmaceuticals Establishes 6 Hours As Optimum Treatment Period For DMT In Neuron Study
01/11/2021 11:08
Nov 1 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS ESTABLISHES 6 HOURS AS OPTIMUM
TREATMENT PERIOD FOR DMT IN NEURON STUDY
Source text for Eikon: ID:nGNXbn1Rlz
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement